Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
Bar-Ad V, Palmer J, Yang H, Cognetti D, Curry J. Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments. Semin Oncol. 2014;41(6):798–806.
Pignon JP, le Maitre A, Maillard E, et al. MACH-NC Collaborative Group: meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomized trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.
Cooper JS, PAJAK TF, Forestiere AA, et al. Postoperative irradiation with or without concomitant chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.
Rubin GJ, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene. 1997;15(4):409–16.
Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666–72.
Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. J Pathol. 1986;149(1):9–14.
Ma X, Huang J, Wu X, et al. Epidermal growth factor receptor could play a prognostic role to predict the outcome of nasopharyngeal carcinoma: a meta-analysis. Cancer Biomark. 2014;14(4):267–77.
Keedy VL, Temin S, Somerfield MR, et al. American society of clinical oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29(15):2121–7.
Sequist LV, von PJ, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29(24):3307–15.
Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29(7):868–74.
Mehra R, Cohen RB, Burtness BA.The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2008;6(10):742–50
Kono SA, Haigentz Jr M, Yom SS, Saba N. EGFR Monoclonal antibodies in the treatment of squamous cell carcinoma of the head and neck: a view beyond cetuximab. Chemother Res Pract. 2012;2012:901320.
Cohen MH, Chen H, Shord S, et al. Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist. 2013;18(4):460–6.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.
Merlano M, Russi E, Benasso M, Corvò R, Colantonio I, et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol. 2007;22(3):712–7.
Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern cooperative oncology group study. J Clin Oncol. 2005;23(34):8646–54.
JPT Higgins SG. Cochrane handbook for systematic reviews of interventions. The Cochrane Library. 2005
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.
Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337–51.
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
Walsh L, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011;98(1):38–41.
Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys. 2008;71(3):676–81.
L. D. Koutcher ES, D. Carlson NK, M. Fury SW, Z. Zhang QM, D. Pfister. Cisplatin (CDDP) and Radiation (RT) versus Cetuximab (C) and RT in the Context ofHuman Papillomavirus (HPV) and P16 in the Treatment of Locally Advanced Head and Neck Cancer (LAHNC). 2012. Annual ASTRO Meeting.
Jensen AD, Krauss J, Weichert W, et al. Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Radiat Oncol. 2011;6:122.
Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):915–22.
Beijer YJ, Koopman M, Terhaard CH, Braunius WW, van Es RJ, de Graeff A. Outcome and toxicity of radiotherapy combined with chemotherapy or cetuximab for head and neck cancer: our experience in one hundred and twenty-five patients. Clin Otolaryngol. 2013;38(1):69–74.
Ley J, Mehan P, Wildes TM, et al. Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. Oncology. 2013;85(5):290–6.
Ye AY, Hay JH, Laskin JJ, Wu JS, Ho CC. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab. J Cancer Res Ther. 2013;9(4):607–12.
Pajares B, Trigo JM, Toledo MD, et al. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer. 2013;13:26.
Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853–9.
M. Ghi AP, R. Orecchia SP, F. Bertoni NM. A Phase 2-3 Study Comparing Concomitant Chemoradiation Therapy (CRT) Versus Cetuximab/RT (CET/RT) With or Without Induction Docetaxel/Cisplatin/5-Fluorouracil (TPF) in Locally-Advanced Head and Neck Squamous Cell Carcinoma (LASCCHN) e Efficacy Results of the GSTTC Italian Study (NCT01086826). Int J Radiat Oncol Biol Phys. 2013 [eAbstract] .
N. Riaz AB, D. Adkins SR, J. Huang PC, J. Ley DK, W. Thorstad NL. Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck (LA-HNSCC): Can HPV Help Decide Which Agent. Int J Radiat Oncol Biol Phys 2008 [eAbstract].
Hu MH, Wang LW, Lu HJ, et al. Cisplatin-based chemotherapy versus cetuximab in concurrent chemoradiotherapy for locally advanced head and neck cancer treatment. Biomed Res Int. 2014;2014:904341.
Levy A, Blanchard P, Bellefqih S, et al. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlenther Onkol. 2014;190(9):823–31.
Tang C, Chan C, Jiang W, et al. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck. 2015;37(3):386–92.
Fayette J, Bonnin N, Ferlay C, et al. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients. Anticancer Drugs. 2013;24(6):623–9.
Huang J, Baschnagel AM, Chen P, et al. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer. Int J Clin Oncol. 2014;19(2):240–6.
Shapiro LQ, Sherman EJ, Riaz N, et al. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncol. 2014;50(10):947–55.
Kanakamedala MR SPG, Abraham RS AAA, Vijayakumar S aRDH. Comparison of Cisplatin Versus Cetuximab With Intensity Modulated Radiation Therapy in Locally Advanced Squamous Cell Carcinomas of Head and Neck: Toxicity, Patterns of Failure, and Survival Analysis. Radiat Oncol. 2014;90(15). Annual ASTRO Meeting.
N. Riaz AB, D. Adkins SR, J. Huang PC, J. Ley DK, W. Thorstad NL. Multi-institution Analysis of Concurrent Chemoradiation Therapy With Cisplatin (CDDP) Versus Cetuximab (C225) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LAHNSCC): Can HPV Help Decide Which Agent. Int J Radiat Oncol Supplement 2014 [eAbstract].
Peddi P, Shi R, Nair B, Ampil F, Mills GM, Jafri SH. Cisplatin, cetuximab, and radiation in locally advanced head and neck squamous cell cancer: a retrospective review. Clin Med Insights Oncol. 2015;9:1–7.
S. L. Galper HD, Decker MGRaRH. Cetuximab versus cisplatin concurrent with IMRT in locally advanced head and neck cancer (LAHNC). J Clin Oncol ASCO Annual Meeting. 2009. 27(e17030).
Delphine Borchiellini CD, Jocelyn Gal BL, Marc Alfonsi KB, Christian Righini BG, Beltran M. Induction TPF followed by chemoradiation or radiotherapy-cetuximab in nonresectable advanced head and neck squamous cell carcinoma: A retrospective study in 164 patients . Int J Radiat Oncol. 2012;30(e16044).
Strom TJ, et al. Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol. 2015;51(7):704–8.
Riaz N, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2016;39(1):27–31.
Magrini SM, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016;34(5):427–35.
Network NCC. NCCN head and neck cancers guidelines (Version 1, 2016). America: NCCN; 2016.
Robert F, Ezekiel MP, Spencer SA, Meredith RF, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiationtherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19(13):3234–43.
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.
Petrelli F, Coinu A, Riboldi V, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol. 2014;50(11):1041–8.
Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.
Gillison ML, Harris J, Westra W, et al. Survival outcomes bytumor human papillomavirus (HPV) in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129 [Abstract]. Proc Am SocClinOncol 2009;27(Suppl.):15 s .
Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15.
Riaz N, Sherman E, Koutcher L, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2014.
Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011;100(1):33–40.
Lill C, Kornek G, Bachtiary B, Selzer E, et al. Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced.Wien Klin Wochenschr. 2011;123(7–8):215–21.
Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75.
Termine N, Panzarella V, Falaschini S, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol. 2008;19(10):1681–90.
Koutcher LD, Wolden S, Lee N. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am J Clin Oncol. 2009;32(5):472–6.
Elliott EA, et al. Phase III Trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Trial 99-13. J Clin Oncol. 2006;24(13):2092–7.
Dorr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol. 2001;61(3):223–31.